Catalyst settles with Teva, staving off Firdapse generic until 2035

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med Firdapse, Catalyst Pharmaceutical has repeatedly emerged triumphant over its detractors.

Now, the Florida-based drugmaker has parried another Firdapse challenger in Teva Pharmaceuticals, which had hoped to market a generic version of the Lambert-Eaton myasthenic syndrome (LEMS) drug before its U.S. patents run out.